Metastatic HER2-Positive Breast Cancer: Management, Challenges, and Future Directions

HER2 is over-expressed or amplified in 15 –20% of breast cancer. Significant progress has been made in the treatment of metastatic HER2+ breast cancer. This is largely due to successful targeting of the HER2 pathway. There are several approved agents in the metastatic setting. However, treatment resistance frequently develops and tumors e ventually progress. In recent years, our understanding of mechanisms of resistance has evolved. It is generally accepted now that HER2-positive breast cancer is not one disease.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Tags: Massarweh: Breast Cancer Source Type: research